---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002863"
form_type: "8-K"
ticker: "ONCY"
cik: "0001129928"
company_name: "ONCOLYTICS BIOTECH INC"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:46:52.675893+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Oncolytics: GOBLET Cohort 4 third-line anal cancer ORR 29%; median DOR ~17 months; files new patent application

## Summary
- GOBLET Cohort 4: 4/14 evaluable third-line anal cancer patients responded (ORR 29%), 2 CRs, 2 PRs; median DOR ~17 months vs historical ~10%.
- Second-line anal cancer: pelareorep + atezolizumab achieved 30% ORR (vs 13.8% standard of care), median DOR 15.5 months (vs 9.5 months).
- Company planning Type C meeting with FDA in Q1 2026 to discuss accelerated approval pathway for third-line anal cancer.
- Filed Track 1 patent application for pelareorep manufacturing; expects final USPTO action in Q3 2026; claims could extend to 2044.
- Additional patent applications planned for manufacturing and method-of-use to potentially extend coverage beyond 2044.

## SEC filing metadata
- accession: 0001104659-26-002863
- form_type: 8-K
- ticker: ONCY
- cik: 0001129928
- company_name: ONCOLYTICS BIOTECH INC
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1129928/000110465926002863/0001104659-26-002863-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1129928/000110465926002863/tm262940d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002863
- JSON: https://secwatch.observer/filing/0001104659-26-002863.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002863.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.